Samsung Biologics, a South Korea–based biopharmaceutical contract development and manufacturing organization (CDMO), has secured new contracts worth a combined $319 million with pharmaceutical companies in Europe and Asia, pushing its total orders this year past $2.19 billion, the company announced on May 26.
The two latest deals—valued at $175 million and $144 million, respectively—cover contract manufacturing services through the end of 2030 and 2033.
While client names and product details remain confidential, the agreements signal continued global demand for the company’s large-scale biologics production capabilities.
With these additions, Samsung Biologics has signed four publicly disclosed contracts so far in 2024. The company has won deals across North America, Asia, and Europe, reaching $2.37 billion in cumulative order volume—over 60% of last year’s full-year total of $3.94 billion—within just five months.
Samsung Biologics currently counts 17 of the top 20 global pharmaceutical firms as clients. Its competitive edge lies in large-scale capacity, high product quality, and an extensive regulatory track record. Since its founding, the company’s cumulative contract value has exceeded $18.2 billion.
To meet rising global demand for biologics, Samsung Biologics continues to expand its manufacturing capacity. Its fifth plant, launched in April, adds 180,000 liters of production capacity—bringing the company’s total capacity to 784,000 liters, the largest in the world.
The company is also recognized for its operational excellence. In 2023, it achieved a 99% batch success rate, and as of April 2025, it has obtained 356 manufacturing approvals from major regulatory agencies in the U.S., Europe, and Japan. The number of approvals continues to rise alongside capacity expansion, with industry-leading inspection clearance rates.
